OR WAIT null SECS
Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.
Nordic Capital, a healthcare and technology investor, has acquired a majority share in IntegriChain, a provider of pharmaceutical technology, data, consulting, and outsourcing solutions. The terms of the deal were not disclosed.
IntegriChain offers a fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while helping patients have access to affordable, timely, and sustainable access to therapy. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016.
The company’s integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables the pharma sector in further achieving better commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net (GTN).
“We’re pleased to have Nordic Capital as a new partner to support us on our journey. We are immensely proud of the team at IntegriChain and how we help pharma manufacturers deliver winning commercialization strategies while optimizing their net revenue,” says Josh Halpern, co-founder and CEO of IntegriChain. “ … We thank Accel-KKR for their many years of sound guidance and support to help us ready IntegriChain for this important next phase of our business development.”
Nordic Capital executives also see this investment as a promising one.
“IntegriChain has established a significant position over the last 17 years as a leader in access and commercialization for life sciences—helping manufacturers of all size from strategy to operational execution. We are confident that the company will continue its already strong record of growth by helping customers address their most pressing market access challenges as the industry evolves,” notes Daniel Berglund, co-head of healthcare, Nordic Capital Investment Advisors. “The fact that IntegriChain supports more than 400 pharmaceutical customers speaks to the quality of the platform, data, and services they provide.”
For more information regarding IntegriChain, including its recent Access Insights Conference, visit Pharma Commerce’s conference coverage page.
1. Nordic Capital acquires majority share in IntegriChain, the only fully integrated platform for pharma commercialization and market access. IntegriChain. News release. November 8, 2023. Accessed November 10, 2023. https://www.integrichain.com/news/nordic-capital-acquires-majority-share-in-integrichain-the-only-fully-integrated-platform-for-pharma-commercialization-and-market-access/